DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket Nos. FDA–2013–M–1321, FDA–2013–M–1322, FDA–2013–M–1323, FDA–2013–M–1362, FDA–2013–M–1363, FDA–2013–M–1364, FDA–2013–M–1365, FDA–2013–M–1488, and FDA–2013–M–1605]

Medical Devices; Availability of Safety and Effectiveness Summaries for Premarket Approval Applications

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is publishing a list of premarket approval applications (PMAs) that have been approved. This list is intended to inform the public of the availability of safety and effectiveness summaries of approved PMAs through the Internet and the Agency's Division of Dockets Management.

ADDRESSES: Submit written requests for copies of summaries of safety and effectiveness data to the Division of Dockets Management (HFA–305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. Please cite the appropriate docket number as listed in table 1 when submitting a written request. See the **SUPPLEMENTARY INFORMATION** section for electronic access to the summaries of safety and effectiveness.

FOR FURTHER INFORMATION CONTACT: Nicole Wolanski, Center for Devices and Radiological Health, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 66, rm. 1650, Silver Spring, MD 20993–0002, 301–796–6570.

SUPPLEMENTARY INFORMATION:

I. Background

In accordance with sections 515(d)(4) and (e)(2) of the Federal Food, Drug, and Cosmetic Act (the FD&C Act) (21 U.S.C. 360e(d)(4) and (e)(2)), notification of an order approving, denying, or withdrawing approval of a PMA will continue to include a notice of opportunity to request review of the order under section 515(g) of the FD&C Act. The 30-day period for requesting reconsideration of an FDA action under § 10.33(b) (21 CFR 10.33(b)) for notices announcing approval of a PMA begins on the day the notice is placed on the Internet. Section 10.33(b) provides that FDA may, for good cause, extend this 30-day period. Reconsideration of a denial or withdrawal of approval of a PMA may be sought only by the applicant; in these cases, the 30-day period will begin when the applicant is notified by FDA in writing of its decision.

The regulations provide that FDA publish a quarterly list of available safety and effectiveness summaries of PMA approvals and denials that were announced during that quarter. The following is a list of approved PMAs for which summaries of safety and effectiveness were placed on the Internet from October 1, 2013, through December 31, 2013. There were no denial actions during this period. The list provides the manufacturer's name, the product's generic name or the trade name, and the approval date.

TABLE 1—LIST OF SAFETY AND EFFECTIVENESS SUMMARIES FOR APPROVED PMAS MADE AVAILABLE FROM OCTOBER 1, 2013, THROUGH DECEMBER 31, 2013

PMA No., Docket No.	Applicant	Trade Name	Approval Date
P040043/S051, FDA–2013–M–1323	W.L. Gore & Associates, Inc	GORE® TAG® Thoracic Endoprosthesis	September 10, 2013.
P970053/S011, FDA–2013–M–1362	Nidek Co., Ltd	Nidek EC–5000 Excimer Laser System	September 30, 2013.
P020050/S012, FDA–2013–M–1321	Alcon Research, Ltd	ALLEGRETTO WAVE® Eye-Q Excimer Laser System.	October 2, 2013.
H120005, FDA–2013–M–1322	Kaneka Pharma America LLC	Kaneka Liposorber® LA–15 System	October 10, 2013.
P130005, FDA–2013–M–1363	Cardiovascular Systems, Inc	Diamondback 360® Coronary Orbital Arthrectomy System.	October 21, 2013.
P110033, FDA–2013–M–1364	Allergan	JUVÉDERM® VOLUMA™ XC	October 22, 2013.
P100009, FDA–2013–M–1365	Abbott Vascular	MitraClip Clip Delivery System (MitraClip CDS).	October 24, 2013.
P100026, FDA–2013–M–1488	NeuroPace, Inc	RNS® System	November 14, 2013.
P130006, FDA–2013–M–1605	W.L. Gore & Associates, Inc	GORE® VIABAHN® Endoprosthesis & GORE® VIABAHB® Endoprosthesis with Heparin BioActive Surface.	December 5, 2013.

II. Electronic Access

Persons with access to the Internet may obtain the documents at *http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/PMAApprovals/default.htm.*

Dated: March 7, 2014.

Leslie Kux,

Assistant Commissioner for Policy.

[FR Doc. 2014–05429 Filed 3–11–14; 8:45 am]

BILLING CODE 4160–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket Nos. FDA–2013–M–0851, FDA–2013–M–0987, FDA–2013–M–0988, FDA–2013–M–1017, FDA–2013–M–1095, FDA–2013–M–1159, and FDA–2013–M–1206]

Medical Devices; Availability of Safety and Effectiveness Summaries for Premarket Approval Applications

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is publishing a list of premarket approval applications (PMAs) that have been approved. This list is intended to inform the public of the availability of safety and effectiveness summaries of approved PMAs through the Internet and the Agency's Division of Dockets Management.

ADDRESSES: Submit written requests for copies of summaries of safety and effectiveness data to the Division of Dockets Management (HFA–305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. Please cite the appropriate docket number as listed in table 1 when submitting a written request. See the **SUPPLEMENTARY INFORMATION** section for

electronic access to the summaries of safety and effectiveness.

FOR FURTHER INFORMATION CONTACT: Nicole Wolanski, Center for Devices and Radiological Health, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 66, Rm. 1650, Silver Spring, MD 20993–0002, 301–796–6570.

SUPPLEMENTARY INFORMATION:

I. Background

In accordance with sections 515(d)(4) and (e)(2) of the Federal Food, Drug, and Cosmetic Act (the FD&C Act) (21 U.S.C. 360e(d)(4) and (e)(2)), notification of an order approving, denying, or withdrawing approval of a PMA will continue to include a notice of opportunity to request review of the order under section 515(g) of the FD&C Act. The 30-day period for requesting reconsideration of an FDA action under § 10.33(b) (21 CFR 10.33(b)) for notices announcing approval of a PMA begins on the day the notice is placed on the Internet. Section 10.33(b) provides that FDA may, for good cause, extend this 30-day period. Reconsideration of a denial or withdrawal of approval of a PMA may be sought only by the applicant; in these cases, the 30-day period will begin when the applicant is notified by FDA in writing of its decision.

The regulations provide that FDA publish a quarterly list of available safety and effectiveness summaries of PMA approvals and denials that were announced during that quarter. The following is a list of approved PMAs for which summaries of safety and effectiveness were placed on the Internet from July 1, 2013, through September 30, 2013. There were no denial actions during this period. The list provides the manufacturer's name, the product's generic name or the trade name, and the approval date.

TABLE 1—LIST OF SAFETY AND EFFECTIVENESS SUMMARIES FOR APPROVED PMAS MADE AVAILABLE FROM JULY 1, 2013, THROUGH SEPTEMBER 30, 2013

PMA No., Docket No.	Applicant	Trade name	Approval date
P120022, FDA–2013–M–0851	QIAGEN Manchester Ltd	*therascreen*® EGFR RGQ PCR Kit	July 12, 2013.
P110002, FDA–2013–M–0987	LDR Spine USA, Inc	Mobi-C® Cervical Disc Prosthesis	August 7, 2013.
P120009, FDA–2013–M–0988	PFM Medical AG	Nit-Occlud® PDA	August 16, 2013.
P120004, FDA–2013–M–1017	Parascript, LLC	Parascript® *Accu*Detect® 6.1.0	August 22, 2013.
P110009, FDA–2013–M–1095	LDR Spine USA, Inc	Mobi-C® Cervical Disc Prosthesis	August 23, 2013.
P110040, FDA–2013–M–1159	Medtronic Vascular	Medtronic Vascular Complete® SE Vascular Stent System.	September 19, 2013.
P120010, FDA–2013–M–1206	Medtronic, Inc	MiniMed 530G System	September 26, 2013.

II. Electronic Access

Persons with access to the Internet may obtain the documents at *http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/PMAApprovals/default.htm.*

Dated: March 6, 2014.

Leslie Kux,

Assistant Commissioner for Policy.

[FR Doc. 2014–05347 Filed 3–11–14; 8:45 am]

BILLING CODE 4160–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA–2014–N–0253]

Methods for Thrombogenicity Testing; Public Workshop; Request for Comments

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice of public workshop; request for comments.

The Food and Drug Administration (FDA) is announcing the following public workshop entitled ''Workshop on Methods for Thrombogenicity Testing.'' Planned topics of discussion include the optimization of in vitro and in vivo thrombogenicity test methods and the identification of alternative in vitro tests.

Date and Time: The public workshop will be held on April 14, 2014, from 9 a.m. to 5 p.m.

Location: The public workshop will be held at the FDA White Oak Campus, 10903 New Hampshire Ave., Bldg. 31 Conference Center, the Great Room (rm. 1503, sections B and C), Silver Spring, MD 20993–0002. Entrance for the public workshop participants (non-FDA employees) is through Building 1 where routine security check procedures will be performed. For parking and security information, please refer to *http://www.fda.gov/AboutFDA/WorkingatFDA/BuildingsandFacilities/WhiteOakCampusInformation/ucm241740.htm.*

Contact Persons: Anchal Kaushiva, Center for Devices and Radiological Health, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 66, rm. 1266, Silver Spring, MD 20993–0002, 301–796–6330, FAX: 301–847–8115, email: *anchal.kaushiva@fda.hhs.gov*, or James Kleinedler, Center for Devices and Radiological Health, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 66, rm. 1102, Silver Spring, MD 20993–0002, 301–796–9448, FAX: 301–847–8115, email: *james.kleinedler@fda.hhs.gov.*

Registration: Registration is free and available on a first-come, first-served basis. Persons interested in attending this public workshop must register online by April 4, 2014, at 5 p.m., EST. Early registration is recommended because facilities are limited and, therefore, FDA may limit the number of participants from each organization. If time and space permits, onsite registration on the day of the workshop will be provided beginning at 8 a.m.

If you need special accommodations due to a disability, please contact Susan Monahan, 301–796–5661, email: *susan.monahan@fda.hhs.gov* no later than April 4, 2014.

To register for the public workshop, please visit FDA's Medical Devices News & Events—Workshops & Conferences calendar at *http://www.fda.gov/MedicalDevices/NewsEvents/WorkshopsConferences/default.htm* and select this public workshop from the posted events list. Please provide complete contact information for each attendee, including name, title, and affiliation, email, and telephone number. Those without Internet access should contact Susan Monahan to register. Registrants will receive confirmation after they have been accepted. You will be notified if you are on a waiting list.

Streaming Webcast of the Public Workshop: This public workshop will also be Webcast. Persons interested in viewing the Webcast must register online by April 4, 2014, at 5 p.m. Early registration is recommended because